Sanofi and pCPA Sign Letter of Intent for Dupixent in Four Indications
Updated
Sanofi and the pan-Canadian Pharmaceutical Alliance (pCPA) have signed a Letter of Intent covering Dupixent (dupilumab) across four indications in dermatology and respiratory care, according to a release carried by Investing News Network. The arrangement bundles multiple uses of a single biologic into one access negotiation. The molecule is derived from a living organism rather than synthesized chemically, and the all-indication structure has grown more common as manufacturer pipelines overlap across disease areas.
What the LOI actually changes
A Letter of Intent in the pCPA process is a non-binding agreement in principle. It precedes the Product Listing Agreement, the binding contract that sets price and conditions for public reimbursement. The LOI signals that pricing discussions have reached a stage the alliance considers workable. It does not, by itself, place a drug on any provincial formulary, the schedule of medicines a public plan will cover.
Each province then signs its own agreement and issues its own listing decision. That step has historically added months after an LOI is announced, and some provinces also negotiate parallel agreements through the alliance's separate pricing streams. For prescribers, the practical question is therefore not the LOI itself but the resulting listings. The gap between announcement and reimbursement is where access gains or stalls.
Why one molecule can carry four indications
Dupilumab targets the IL-4 receptor alpha subunit. That receptor is shared by the cytokines IL-4 and IL-13, two signaling proteins that drive type 2 inflammation, the antibody- and allergy-linked branch of the immune response. That shared mechanism is why the same product can address more than one allergic or inflammatory disease. Bundling indications into one negotiation reduces duplication and can accelerate access for uses that would otherwise queue behind earlier listings.
This is also why the dermatology community is paying attention. Atopic dermatitis, a chronic, intensely itchy inflammatory skin condition, was the first dermatology indication for dupilumab. Canadian public plans have listed it for years through indication-by-indication negotiations. The LOI suggests Sanofi and the alliance are now working to harmonize that access across additional uses in a single process, rather than running four separate negotiations.
What the announcement does not say
The release names none of the four indications. It does not list the participating provinces or federal programs. It does not state an effective date, a pricing status, or an estimated timeline to listing. The headline also does not clarify whether existing Dupixent agreements, including prior atopic dermatitis listings, will be folded into the new arrangement or continue on their current terms.
This is the part that warrants scrutiny. A wide LOI can read as access progress, or it can function as a procedural placeholder while the harder terms are negotiated in private. pCPA negotiations are confidential by design. The public typically sees the indication list only when a Product Listing Agreement closes. Without that list, the participating jurisdictions, or the conditions attached, the announcement's practical weight for Canadian dermatology patients and prescribers cannot yet be measured.
What to watch next
The next concrete signal will be the disclosure of participating provinces and the indication list, typically released through a joint pCPA and manufacturer statement. Until those details appear, the LOI marks procedural momentum, not yet a change in what a Canadian dermatologist can prescribe through a public plan tomorrow. Watch the indication list and the province roster. Treat the announcement as the start of a process, not its conclusion.
Source: Google News: Dermatology
Amara Osei
Show full bio
Correspondent covering technology and product news in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.